Table 1

Baseline characteristics of AAP-treated and ENZ-treated patients

AAP (n=46)ENZ (n=59)P values
Age, years, median (range)n=46
73 (53–90)
n=59
76 (60–92)
0.083
LDH at baseline, IU/L, median (range)n=21
226.00 (130–1207)
n=20
229.50 (170–837)
0.755
ALP at baseline, IU/L, median (range)n=37
94.00 (34–2435)
n=46
91.00 (47–4344)
0.781
PSA at baseline, ng/mL, median (range)n=46
15.56 (1.1–588)
n=59
36.00 (1.3–450)
0.605
Gleason score at initial diagnosis, n (%)0.944
 ≤724 (52.2)29 (49.2)
 ≥818 (39.1)25 (42.4)
 Missing4 (8.7)5 (8.5)
ECOG performance score, n (%)0.627
 0/141 (89.1)49 (83.1)
 ≥24 (8.7)7 (11.9)
 Missing1 (2.2)3 (5.1)
Any visceral metastases, n (%)0.646
 No40 (87.0)53 (89.8)
 Yes6 (13.0)6 (10.2)
Anaemia, n (%)0.810
 Grade ≤239 (84.8)51 (86.4)
 Grade ≥30 (0.0)0 (0.0)
 Missing7 (15.2)8 (13.6)
Opioid use at baseline, n (%)0.694
 No36 (78.3)48 (81.4)
 Yes10 (21.7)11 (18.6)
Sedative use at baseline, n (%)0.281
 No39 (84.8)54 (91.5)
 Yes7 (15.2)5 (8.5)
  • AAP, abiraterone acetate plus prednisone; ALP, alkaline phosphatase; ECOG, Eastern Cooperative Oncology Group.; ENZ, enzalutamide; LDH, lactate dehydrogenase; PSA, prostate-specific antigen.